Coeptis Therapeutics Inc

NASDAQ COEP
$12.27 0.38 3.24%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 23.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
28.79M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
26.52M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
3.07M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
123.09 %

Upcoming events Coeptis Therapeutics Inc

All events
No upcoming events scheduled

Stock chart Coeptis Therapeutics Inc

Stock analysis Coeptis Therapeutics Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-2.92 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
3.32 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-2.85 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.25 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-152.35 -50.00

Price change Coeptis Therapeutics Inc per year

2.80$ 14.66$
Min Max

Summary analysis Coeptis Therapeutics Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Coeptis Therapeutics Inc

Revenue and net income Coeptis Therapeutics Inc

All parameters

About company Coeptis Therapeutics Inc

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology. The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Address:
105 Bradford Road, Wexford, PA, United States, 15090
Company name: Coeptis Therapeutics Inc
Issuer ticker: COEP
ISIN: US19207C1045
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2020-12-17
Sector: Healthcare
Industry: Biotechnology
Site: https://coeptistx.com